Logo
Login
$TRAW
$0.34 -$0.00 (0.41%) Close

Company Executives

$TRAW Management Team

Dr. Robert Redfield

Chief Medical Officer

Age 73
Compensation -
Sex Male

Dr. Iain Dukes

Chief Executive Officer

Director

Age 66
Compensation -
Sex Male

Dr. Nikolay Savchuk

Chief Operating Officer

Director

Age 56
Compensation -
Sex Male

Dr. C. David Pauza

Chief Scientific Officer

Virology

Age 71
Compensation -
Sex Male

Mr. Charles Parker

Chief Financial Officer

Age 45
Compensation -
Sex Male

Mr. Jack Stover

Independent Chairman of the Board

Age 69
Compensation $226.5K USD
Sex Male

Board of Directors

From the proxy statement filed May 29, 2026
Directors
7
serving now
Independent
1 of 1
stated in the proxy; 6 not stated
Average tenure
3.9 years
from year joined
CEO also chairs the board
No
Jack E. Stover
Director Age On board Independent Committees Other public boards 2025 pay Source
Iain Dukes
CEO, Executive officer
 67 2024
2 years
 Not stated None stated Iovance Biotherapeutics Inc. Paid as CEO
Jack E. Stover
Board chair
 73 2016
10 years
 Not stated None stated Profusa, Inc. $340,887
Werner Cautreels
73 2024
2 years
 Not stated None stated None stated Not stated
Nikolay Savchuk
Executive officer
 57 2024
2 years
 Not stated None stated None stated Not stated
Trafford Clarke
68 2022
4 years
 Not stated None stated None stated Not stated
M. Teresa Shoemaker
65 2020
6 years
 Not stated None stated None stated $215,887
John Leaman
53 2025
1 year
 Independent
Audit Committee Compensation Committee
None stated $87,733

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

9 disclosed in the proxy filed May 29, 2026
Viriom, Inc.
Nikolay Savchuk serves as President of Viriom and holds investment control of it; Iain Dukes served as its CEO until December 2024
Amount not stated
January 1, 2025 through December 2025 and year ended December 31, 2024

Master Research and Development Agreement under which Viriom provided virology services; Company incurred R&D expense for Viriom services

With Trawsfynydd (now the Company) Open in proxy
Viriom, Inc.
Nikolay Savchuk serves as President of Viriom and holds investment control of it; Iain Dukes served as its CEO until December 2024
$2,350,000 in cash
September 9, 2025

Asset Purchase Agreement under which the Company bought certain pyrrolidine antiviral compound intellectual property assets from Viriom

With Company Open in proxy
Viriom, Inc.
Nikolay Savchuk serves as President of Viriom and holds investment control of it; Iain Dukes served as its CEO until December 2024
Amount not stated

Exclusive royalty-free license to Viriom patents and technical information; no annual fees, royalties or milestone payments required

With Trawsfynydd (now the Company) Open in proxy
ChemDiv, Inc.
Nikolay Savchuk is a stockholder of ChemDiv and a member of its board of directors
Amount not stated
years ended December 31, 2025 and 2024

Master Research and Development Agreement under which ChemDiv provided preclinical drug discovery services; Company incurred R&D expense

With Trawsfynydd (now the Company) Open in proxy
Immediate family member of Nikolay Savchuk
Immediate family member of Dr. Savchuk had a significant ownership interest in Expert
$149,000
2024

Master Research and Development Agreement under which Expert provided drug development and consulting services; R&D expense recorded

With Expert Systems, Inc. Open in proxy
TPAV LLC
Nikolay Savchuk is the sole manager on the board of managers of TPAV
$9,499,995
April 1, 2024

Securities purchase of Company common stock and Series C Preferred Stock in connection with the Trawsfynydd acquisition

With Company Open in proxy
TPAV LLC
Nikolay Savchuk is the sole manager on the board of managers of TPAV
$491,664
December 29, 2024

Purchase of Class B Units (pre-funded warrants and Series A Warrants) under the December 2024 Purchase Agreement

With Company Open in proxy
Werner Cautreels
Former Chief Executive Officer and member of the Board
$491,664
December 29, 2024

Purchase of Class B Units (pre-funded warrants and Series A Warrants) under the December 2024 Purchase Agreement

With Company Open in proxy
TPAV LLC
Nikolay Savchuk is the sole manager on the board of managers of TPAV
$400,000.05
April 15, 2026

Purchase of common stock and Series A, B and C warrants under a securities purchase agreement with certain investors

With Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans